Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon.
Interferon was used to treat C57BL/6 female mice inoculated with a continuous line of murine osteogenic sarcoma cells. A short 7-day course of 30,000--60,000 U/day of tpe I interferon either completely inhibited or delayed the appearance of tumors in experimental animals. The therapeutic efficacy of type I interferon was compared with murine serum that contained type II interferon as well as other lymphokine activity. Tumor development was strikingly inhibited in animals treated for 7 days with serum containing only 600 U of type II interferon. Inhibition of tumor development was thus achieved with 100-fold less interferon than that required with type I preparation.
D000818:Animals; D005260:Female; D007372:Interferons / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D051379:Mice; D008810:Mice, Inbred C57BL; D012516:Osteosarcoma / Q000188:drug therapy; D012513:Sarcoma, Experimental / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy
D007372:Interferons